Thursday , May 25 2017
Home / Endocrinology

Endocrinology

Novartis Enters Deal to Use Parvus’ Navacim Technology to Develop and Commercialize Type 1 Diabetes Drugs

CALGARY, Alberta–(BUSINESS WIRE)–Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune suppression, has entered into a license and collaboration agreement with Novartis for its lead Navacim for treating type 1 diabetes. Navacims constitute a novel pharmacological class of therapeutic comprised of …

Read More »

Rates of New Diagnosed Cases of Type 1 and 2 Diabetes on the Rise Among Children, Teens

Rates of new diagnosed cases of type 1 and type 2 diabetes are increasing among youth in the United States, according to a report, Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012, published today in the New England Journal of Medicine. In the United States, 29.1 …

Read More »

Two Prime Therapeutics Studies Examine Diabetes Costs, How Appropriate Preventive Care Can Improve Outcomes

ST. PAUL, Minn.–(BUSINESS WIRE)–Two new studies find commercially insured members with diabetes had 2.5 times higher medical and pharmacy spending than members without diabetes matched by age, sex, state of residence and insurer. But those taking a cholesterol-lowering statin for primary prevention of heart disease – a common complication of …

Read More »

Enteris BioPharma and Sanofi Enter Deal to Develop Oral Diabetes Drug

BOONTON, N.J., Jan. 23, 2017 /PRNewswire/ — Enteris BioPharma, Inc., announced today the initiation of a feasibility study agreement with Sanofi to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence™, to develop an oral formulation of one of Sanofi’s preclinical stage peptides. Joel Tune, Chief …

Read More »

FDA Approves Synjardy XR Tablets for Adults with Type 2 Diabetes

RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 12, 2016 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Synjardy® XR (empagliflozin and metformin hydrochloride extended-release) tablets for adults with type 2 diabetes. When used along with diet and exercise, SYNJARDY XR is indicated to improve blood sugar in adults with …

Read More »

FDA Warns Diabetes Drug Pioglitazone May Increase Risk of Bladder Cancer

[12-12-2016 ] As a result of an updated review, the U.S. Food and Drug Administration (FDA) has concluded that use of the type 2 diabetes medicine pioglitazone (Actos, Actoplus Met, Actoplus Met XR, Duetact, Oseni) may be linked to an increased risk of bladder cancer. The labels of pioglitazone-containing medicines …

Read More »

FDA Approves Jardiance to Reduce CV Risk in Patients with Type 2 Diabetes

RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 5, 2016 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) approved a new indication for Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. JARDIANCE is the first type 2 diabetes treatment approved with …

Read More »

FDA Approves Sanofi’s Soliqua for Treatment of Type 2 Diabetes

Paris, France – November 21, 2016 – Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved once-daily Soliqua (TM) 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL & 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 …

Read More »

Novo Nordisk’s Diabetes Drug Xultophy Wins FDA Approval

PLAINSBORO, N.J., Nov. 21, 2016 /PRNewswire/ — Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for Xultophy®100/3.6 (insulin degludec 100 units/mL and liraglutide 3.6 mg/mL injection). Xultophy® 100/3.6 is a once-daily, combination of Tresiba® (insulin degludec …

Read More »

FDA Grants Orphan Drug Designation to Genexine’s Investigational Growth Hormone Deficiency Drug

SEONGNAM, South Korea–(BUSINESS WIRE)–Genexine (KOSDAQ: 095700), an innovative biotechnology company focused on immuno-oncology, metabolic and orphan diseases, announced today that US FDA Office of Orphan Products Development (OOPD) has granted GX-H9 an orphan drug designation for the treatment of growth hormone deficiency. GX-H9 is next-generation, long-acting recombinant human growth hormone …

Read More »